CrystalO Biopharma was established in August 2019, adhering to the mission of "developing drugs with minimal side effects by precisely targeting ion channels, and bringing a better life through technology and innovation." We are committed to the research and development of drugs for Neurological andpsychiatric disorders, chronic kidney disease, and cardiovascular diseases. We aspire to become one of the most innovative and influential company globally. To date, we have successfully completed financing exceeding 100 million RMB.
The core team of the company is composed of PhDs from top research institutes and pharmaceutical companies, such as Harvard University and the Shanghai Institute of Materia Medica.And we invited Erwin Neher, the Nobel Laureate in Physiology or Medicine and founder of the ion channel field, as the company's Chief Scientific Advisor. We are at the global forefront in the discovery of new ion channel targets, activity testing, and drug development based on structure and artificial intelligence.
In 2020, we won “the first prize in the biomedical industry of the Shenzhen Innovation and Entrepreneurship Competition”, “the ‘Science and Innovation China’ Pioneer Technology Award in 2020”, “the National Excellence Award of the 9th China Innovation and Entrepreneurship Competition”, “the TOP10 of the Science and Innovation China Science and Technology Innovation and Entrepreneurship Competition”, “and the ‘Specialized, Fine, Special, and New’ SME award in Shenzhen”.